Revenue: As of FY2025 Q3, the actual value is USD 653 M.EPS: As of FY2025 Q3, the actual value is USD -12.7.EBIT: As of FY2025 Q3, the actual value is USD 77.6 M.<h3>Segment Revenue</h3><ul><li>Total Revenue: Bio-Rad Laboratories, Inc. reported total net sales of $653.0 million for Q3 2025, a 0.5% increase from $649.7 million in Q3 2024. On a currency-neutral basis, sales decreased by 1.7%.</li><li>Life Science Group: Net sales were $261.8 million, a 0.3% increase from the same period in 2024. Currency-neutral sales decreased by 1.5% due to constrained academic research and biotech funding.</li><li>Clinical Diagnostics Group: Net sales were $391.2 million, a 0.6% increase from the same period in 2024. Currency-neutral sales decreased by 1.8%, primarily due to lower reimbursement rates for diabetes testing in China.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income (Loss): The company reported a net loss of - $341.9 million for Q3 2025, compared to a net income of $653.2 million in Q3 2024. This loss was significantly impacted by a change in the fair market value of its investment in Sartorius AG.</li><li>Gross Margin: The GAAP gross margin was 52.6% in Q3 2025, down from 54.8% in Q3 2024. The non-GAAP gross margin was 53.5%, down from 55.6%.</li><li>Income from Operations: GAAP income from operations was $65.3 million, with an operating margin of 10.0%. Non-GAAP income from operations was $77.0 million, with an operating margin of 11.8%.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash provided by operating activities was $367.3 million for the nine months ended September 30, 2025, compared to $331.0 million for the same period in 2024.</li><li>Free Cash Flow: Free cash flow was $255.5 million for the nine months ended September 30, 2025, compared to $208.3 million for the same period in 2024.</li></ul><h3>Outlook / Guidance</h3>Bio-Rad Laboratories, Inc. maintains its financial outlook for the full year 2025, expecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent and a non-GAAP operating margin of approximately 12.0 to 13.0 percent.

Bio-Rad Lab-B | 8-K: FY2025 Q3 Revenue: USD 653 M